Skip to main content

Advertisement

Table 4 Outcomes, instruments used, and effects of decisions aids evaluated in the included one-group pretest-posttest design study

From: Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review

Outcomes Instruments used for assessment Pretest-posttest study using the instrument Score (S.D.) p-value Main results
Decision related outcomes
 Decisional conflict Decisional Conflict Scalea Metcalfe 2007 [27] Pre-test 36.2 (16.4), Post-test 23.0 (15.2) 0.001 Significantly less decisional conflict after using the DA.
 Strenght of treatment preference 15-point scale Metcalfe 2007 [27] RR-M:   Significantly fewer women in the DA group were uncertain about RR-M and RR-O.
Pre-test No 14, Yes 3, Unsure 3  
Post-test No 10, Yes 4, Unsure 6 0.009
RR-O:  
Pre-test No 5, Yes 12, Unsure 3  
Post-test No 2, Yes 15, Unsure 3 0.003
Tamoxifen:  
Pre-test No 10, Yes 1, Unsure 9  
Post-test No 11, Yes 5, Unsure 4 0.12
Information related outcomes
 Risk perception BC risk, mutation carriersb Metcalfe 2007 [27] Pre-test 65.1 (16.1), Post-test 73.6 (13.4) 0.05 Significantly better risk perception after using the DA.
BC, risk after RR-M, mutation carriersb Metcalfe 2007 [27] Pre-test 71.8 (22.0), Post-test 84.2 (18.2) 0.005 Significantly better risk perception after using the DA.
BC, risk after RR-O, mutation carriersb Metcalfe 2007 [27] Pre-test 43.2 (20.0), Post-test 65.0 (13.3) 0.001 Significantly better risk perception after using the DA.
BC, risk with Tamoxifen, mutation carriersb Metcalfe 2007 [27] Pre-test 50.0 (19.0), Post-test 56.6 (10.0) 0.17 No significant difference.
BC, risk with mammography, mutation carriersb Metcalfe 2007 [27] Pre-test 21.5 (28.0), Post-test 13.5 (22.8) 0.11 No significant difference.
Health outcomes
 Distress Impact of Event Scalea Metcalfe 2007 [27] Pre-test 22.7 (13.7), Post-test 19.9 (14.5) 0.24 No significant difference.
  1. DA decision aid, BC breast cancer, RR-M risk-reducing mastectomy, RR-O risk-reducing oophorectomy
  2. ainstrument was validated in a study
  3. brisk estimates from 0 to 100%